(Q58207461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Masaru Iwai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Harumi Kanno

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Shinji Inaba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Izumi Senba

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Hirotomo Nakaoka

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Masatsugu Horiuchi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

16 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Hypertension

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

169-174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

Insulin resistance and hyperinsulinemia in hypertension.

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor kappa B kinase and nuclear factor kappa B-inducing kinase

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Cardioprotective effect of benidipine on cardiac performance and remodeling in failing rat hearts

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Nifedipine improves the migratory ability of circulating endothelial progenitor cells depending on manganese superoxide dismutase upregulation

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FAJH.2010.198

7 January 2021

Identifiers

DOI

10.1038/AJH.2010.198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20847723%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference